158 related articles for article (PubMed ID: 32308367)
1. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
8. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
9. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
11. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
12. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
Lee HY; Kim CH; Song JK; Chae SC; Jeong MH; Kim DS; Oh BH
Korean J Intern Med; 2017 Nov; 32(6):1025-1036. PubMed ID: 29032666
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
[TBL] [Abstract][Full Text] [Related]
15. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
[TBL] [Abstract][Full Text] [Related]
17. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
18. Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report.
Park DH; Yun GY; Eun HS; Joo JS; Kim JS; Kang SH; Moon HS; Lee ES; Lee BS; Kim KH; Kim SH
Medicine (Baltimore); 2017 Nov; 96(47):e8905. PubMed ID: 29382024
[TBL] [Abstract][Full Text] [Related]
19. Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study.
Cho EJ; Sung KC; Kang SM; Shin MS; Joo SJ; Park JB
PLoS One; 2019; 14(4):e0214293. PubMed ID: 30964905
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.
Lee HY; Kim KI; Ihm SH; Rhee MY; Sohn IS; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Clin Ther; 2021 Oct; 43(10):1746-1756. PubMed ID: 34503866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
